WuXi PharmaTech (Cayman) Company Profile (NYSE:WX)

Analyst Ratings

Consensus Ratings for WuXi PharmaTech (Cayman) (NYSE:WX) (?)
Ratings Breakdown: 1 Hold Rating(s), 1 Buy Rating(s)
Consensus Rating:Buy (Score: 2.50)
Consensus Price Target: N/A

Analysts' Ratings History for WuXi PharmaTech (Cayman) (NYSE:WX)
Show:
DateFirmActionRatingPrice TargetActions
10/5/2015Morgan StanleyDowngradeOverweight -> Equal WeightView Rating Details  Tweet This Rating  Share This Rating on StockTwits
8/14/2015William BlairReiterated RatingOutperform -> BuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/12/2015Credit Suisse Group AGDowngradeOutperform -> NeutralView Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/6/2015Goldman Sachs Group Inc.DowngradeConviction-Buy -> Neutral$44.50 -> $39.50View Rating Details  Tweet This Rating  Share This Rating on StockTwits
11/21/2014Jefferies GroupDowngradeBuy -> Hold$40.00 -> $38.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 7/23/2014 forward)

Earnings

Earnings History for WuXi PharmaTech (Cayman) (NYSE:WX)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
3/3/2016        
11/3/2015Q3$0.31$0.31$205.24 million$213.60 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/13/2015Q215$0.39$0.38$195.26 million$194.14 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/13/2015Q1$0.32$0.36$174.29 million$180.00 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/5/2015Q414$0.53$0.55$189.54 million$190.60 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/12/2014Q314$0.48$0.54$172.60 million$173.60 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/13/2014Q214$0.47$0.49$162.11 million$163.40 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/14/2014Q114$0.39$0.30$145.00 million$146.70 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/5/2014Q413$0.43$0.53$155.76 million$157.10 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/13/2013Q313$0.39$0.47$145.29 million$146.70 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/12/2013Q2 2013$0.39$0.46$141.10 million$142.33 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/13/2013Q1 2013$0.32$0.35$130.02 million$131.90 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/7/2013Q4 2012$0.30$0.38$123.71 million$125.70 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/12/2012Q312$0.30$0.36$123.17 million$125.84 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/13/2012$0.30$0.33ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/10/2012$0.26$0.33ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/8/2012$0.26$0.31ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/10/2011$0.27$0.31ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for WuXi PharmaTech (Cayman) (NYSE:WX)
No earnings estimates for this company have been tracked by MarketBeat.com

Dividends

Dividend History for WuXi PharmaTech (Cayman) (NYSE:WX)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for WuXi PharmaTech (Cayman) (NYSE:WX)
No insider trades for this company have been tracked by MarketBeat.com

Headlines

Latest Headlines for WuXi PharmaTech (Cayman) (NYSE:WX)
DateHeadline
06/30/16 09:59 AMViral Inactivation Market Worth 573.0 Million USD by 2021
06/23/16 08:08 PMJust Published: "Healthcare Analytical Testing Services Market - Global Forecast to 2021"
06/23/16 09:51 AMRecent research: Virus filtration market size, share, demand and development trends analysis from 2016 to 2021
06/22/16 07:18 PMGlobal virus filtration industry consumption forecast to 2021 scrutinized in new research
06/16/16 07:31 PMViral inactivation market poised to be 573.0 million USD by 2021
06/02/16 07:56 PMWuXi AppTec: genomics player - WuXi PharmaTech, the parent company of WuXi AppTec, is headquarted in Cayman Islands. In 2008, WuXi PharmaTech merged with AppTec Laboratory Services Inc, a US company founded in 2001, with expertise in medical-device and biologics testing. Ge, the founder ...
05/30/16 08:49 AMViral clearance market expected to reach 510.3 million USD by 2020 published by leading research firm - Inc. (U.S.), Lonza Group (Switzerland), Merck KGaA (Germany), Sigma-Aldrich Corporation (U.S.), SGS S.A. (Switzerland), Texcell, Inc. (France), and WuXi PharmaTech (Cayman) Inc. (China).
05/23/16 10:29 AMVirus Filtration Market Worth 3.25 Billion USD by 2020 - Inc. (U.S.), Sigma-Aldrich Corporation (U.S.), Sartorius AG (Germany), Asahi Kasei Medical Co., Ltd. (Japan) and WuXi PharmaTech (Cayman) Inc. (China). About MarketsandMarkets MarketsandMarkets is the world's No. 2 firm in terms of annually published ...
05/17/16 09:18 AMWuXi NextCODE Genomics - Pharmaceuticals & Healthcare - Deals and Alliances Profile - New Market Report - (live-PR.com) - WuXi NextCODE Genomics (WuXi NextCODE), a subsidiary of WuXi PharmaTech (Cayman), Inc., formerly NextCODE Health is a medical device company that offers clinical diagnostics services. The company delivers genomics platform to help ...
05/03/16 05:49 PMNew Market Research Report: Virus Filtration Market - Global Forecast to 2020 - Inc. (U.S.), Sigma-Aldrich Corporation (U.S.), Sartorius AG (Germany), Asahi Kasei Medical Co., Ltd. (Japan) and WuXi PharmaTech (Cayman) Inc. (China). Reasons to Buy the Report: The report will enable both established firms and new entrants to gauge the ...
04/27/16 03:35 AMLabNetwork Forges eCommerce Alliances with Leading Chemical Providers - [at noodls] - SHANGHAI, April 27, 2016 /PRNewswire/ -- LabNetwork, a WuXi AppTec company, held a formal signing ceremony in Shanghai announcing strategic cooperation agreements with 8 top-ranking global chemical providers. ...
04/08/16 06:17 PMAlly Bridge Group Leads $150M Investment In Sorrento Therapeutics - The healthcare-focused private equity firm participated in the US$3.3 billion go-private deal of Chinese pharmaceutical research and development services provider WuXi PharmaTech (Cayman) Inc. That transaction closed in December 2015.
04/04/16 09:45 AMViral Clearance Market Worth 510.3 Million USD by 2020 - Inc. (France), and WuXi PharmaTech (Cayman) Inc. (China). MarketsandMarkets is world's No. 2 firm in terms of annually published premium market research reports. Serving 1700 global fortune enterprises with more than 1200 premium studies in a year ...
03/15/16 05:33 PMCan Wuxi Pharmatech (Cayman) Inc. (NYSE:WX) Surge To $N/A? - Investor Newswire - Can Wuxi Pharmatech (Cayman) Inc. (NYSE:WX) Surge To $N/A?Investor NewswireOne of the most important steps that stockholders take before making an investment is to look for Zacks ABR on a stock. As per the latest update, Wuxi Pharmatech (Cayman) Inc. (NYSE:WX) has an ABR of N/A. The lower this rating, the more confident ...and more »
03/06/16 04:19 PMStock Rating Update on Wuxi Pharmatech (Cayman) Inc. (NYSE:WX) - Investor Newswire - Stock Rating Update on Wuxi Pharmatech (Cayman) Inc. (NYSE:WX)Investor NewswireWuxi Pharmatech (Cayman) Inc. (NYSE:WX) has been issued a N/A rating by the sell-side brokerage firms covering the stock. Basing the rating on a simplified scale where 1 represents a Buy and 5 represents a Sell, this is the average rating based on the ...
02/25/16 05:29 PMWuXi Said to Tap Banks for IPO of $1.5 Billion Biologics Arm - (Bloomberg) -- WuXi PharmaTech (Cayman) Inc., China’s biggest contract medical researcher, has picked banks for an initial public offering of its biologics unit that could value the business at about $1.5 billion, people with knowledge of the matter said.
02/03/16 08:31 AMRatings and Sentiments Alert: Wuxi Pharmatech (Cayman) Inc. (NYSE:WX) - Investor Newswire - Ratings and Sentiments Alert: Wuxi Pharmatech (Cayman) Inc. (NYSE:WX)Investor NewswireZacks Research asks for the recommendation of brokerages to get a consensus rating on any company's stock. Following the methodology, which gives a score to a stock on a 1-5 scale, the stock of Wuxi Pharmatech (Cayman) Inc. (NYSE:WX)'s has been ...and more »
01/31/16 03:27 PMCan Wuxi Pharmatech (Cayman) Inc. (NYSE:WX) Stock Hit $N/A? - Stocks Daily - Can Wuxi Pharmatech (Cayman) Inc. (NYSE:WX) Stock Hit $N/A?Stocks DailyThe report compiled by Zacks Research shows that the stock of Wuxi Pharmatech (Cayman) Inc. (NYSE:WX) has been given an upbeat price target of $N/A by the sell-side experts. The brokerage groups have established the price target of company's stock at ...and more »
01/21/16 08:02 AMWuxi Pharmatech (Cayman) Inc. (NYSE:WX): Earnings Prediction Watch - Investor Newswire - Wuxi Pharmatech (Cayman) Inc. (NYSE:WX): Earnings Prediction WatchInvestor NewswireAccording to sell-side analysts surveyed by Zacks Research, Wuxi Pharmatech (Cayman) Inc. (NYSE:WX) is expected to post earnings per share of $N/A in its most recent fiscal quarter. The company is scheduled to announce the quarterly financial report on ...and more »
01/17/16 08:02 AMWill Wuxi Pharmatech (Cayman) Inc. (NYSE:WX) Meet Analyst Targets? - Investor Newswire - Will Wuxi Pharmatech (Cayman) Inc. (NYSE:WX) Meet Analyst Targets?Investor NewswireMost recently for the quarter ending on N/A, Wuxi Pharmatech (Cayman) Inc. (NYSE:WX) posted a surprise factor of N/A%. The company reported actual earnings of $N/A which was $N/A away from what analysts were projecting on a consensus basis.
12/17/15 11:40 AMAstraZeneca Invests in China, To Buy Respiratory Business -
12/16/15 01:40 AMWuXi and AstraZeneca Form Strategic Alliance to Expedite Development of AstraZeneca's Innovative Biologics Portfolio in China - [PR Newswire] - SHANGHAI, Dec. 16, 2015 /PRNewswire/ -- WuXi AppTec (WuXi), a leading open-access R&D capability and technology platform company serving the global pharmaceutical, biotechnology, and medical device industries, ...
12/13/15 05:00 PMWuXi PharmaTech Presents 2015 Life Science and Chemistry Awards - [PR Newswire] - SHANGHAI, Dec. 13, 2015 /PRNewswire/ -- WuXi PharmaTech (Cayman) Inc., a leading open-access R&D capability and technology platform company serving the pharmaceutical, biotechnology and medical device ...
12/10/15 04:01 PMWuXi PharmaTech (Cayman) Inc. Announces Completion of Going Private Transaction - [at noodls] - WuXi PharmaTech (Cayman) Inc. Announces Completion of Going Private Transaction
12/08/15 12:09 PMWUXI PHARMATECH (CAYMAN) INC. Financials -
12/07/15 07:46 PMWuXi PharmaTech and PRA Health Sciences Restructure Relationship in China - [at noodls] - a325b583-684c-4cef-a5a1-d5125aef776f.pdf SHANGHAI and RALEIGH N.C., December 8, 2015 /PRNewswire-Asia/ -- WuXi PharmaTech (Cayman) Inc. (NYSE: WX), a leading open-access R&D capability and technology platform ...
12/07/15 07:00 AMDr. Ge Li Receives Executive of the Year Award from SCRIP - [PR Newswire] - SHANGHAI , Dec. 7, 2015 /PRNewswire-Asia/ -- WuXi PharmaTech (Cayman) Inc. (NYSE: WX), a leading open-access R&D capability and technology platform company serving the pharmaceutical, biotechnology, and ...
12/02/15 01:42 PMIs Royal Gold, Inc USA) (RGLD) A Good Stock To Buy? -
11/24/15 09:00 PMWuXi PharmaTech Announces Shareholders' Approval of Merger Agreement - [PR Newswire] - SHANGHAI, Nov. 25, 2015 /PRNewswire/ -- WuXi PharmaTech (Cayman) Inc. ("WuXi" or the "Company") (NYSE: WX), a leading open-access R&D capability and technology platform company serving ...
11/24/15 05:50 PMDo Hedge Funds Love WuXi PharmaTech (Cayman) Inc. (ADR) (WX)? -
11/19/15 06:24 AMThe State Of Chinese Company Take-Private Offers: A Look At WuXi PharmaTech -
11/18/15 09:54 AMWuxi PharmaTech (Cayman) Inc. Earnings Q3, 2015 -
11/12/15 04:26 AMGenomics England Contracts With WuXi NextCODE as Clinical Interpretation Partner in Both Rare Disease and Cancer - [at noodls] - 8d91f514-62bc-4a52-94d8-3907004e36ec.pdf FOR IMMEDIATE RELEASE Genomics England Contracts with WuXi NextCODE as Clinical Interpretation Partner in both Rare Disease and Cancer LONDON; SHANGHAI; CAMBRIDGE, ...
11/11/15 11:01 AMISS and Glass Lewis Recommend that WuXi PharmaTech Shareholders Vote "FOR" the Proposed Going-Private Transaction -
11/10/15 03:30 PMWuXi PharmaTech and Lilly Announce Strategic Collaboration to Develop Novel Therapeutic in China -

Social

About WuXi PharmaTech (Cayman)

WuXi PharmaTech (Cayman) logoWuXi PharmaTech (Cayman) Inc. is a pharmaceutical, biotechnology and medical device research and development (R&D) services company, with operations in China and the United States. The Company provides a portfolio of laboratory and manufacturing services throughout the drug and medical device R&D process to its customers. It conducts its operations in two segments: Laboratory services and Manufacturing services. The Company offers Laboratory services for pharmaceutical, biotechnology and medical device companies. It offers Manufacturing services, which include the development of manufacturing processes and the production of advanced intermediates and active pharmaceutical ingredients (APIs) for use by pharmaceutical companies in preclinical and clinical trials of small-molecule products and in commercial products, as well as the production of biologic products.

Industry, Sector and Symbol:
  • Sector: Healthcare
  • Industry: Medical Laboratories & Research
  • Sub-Industry: N/A
  • Exchange: NYSE
  • Symbol: WX
  • CUSIP:
Key Metrics:
  • Previous Close: $0.00
  • 50 Day Moving Average: $45
  • 200 Day Moving Average: $43
  • P/E Ratio: N/A
  • P/E Growth: 0
  • Market Cap: $N/A
  • Current Year EPS Consensus Estimate: $1.51 EPS
  • Next Year EPS Consensus Estimate: $1.77 EPS
Additional Links:
WuXi PharmaTech (Cayman) (NYSE:WX) Chart for Saturday, July, 23, 2016